Latest Sacace Biotechnologies News & Updates
See the latest news and media coverage for Sacace Biotechnologies. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of PCR diagnostic kits
sacace.com- Headquarters
- Como, Italy
- Founded year
- 2001
- Company type
- Partnership
- Number of employees
- 10–50
Latest news about Sacace Biotechnologies
Company announcements
-
Sacace introduces COVID-19 SARS-CoV-2 Variant Typing Real-TM kit
The multiplex Real Time PCR kit detects mutations HV 69-70 DEL, N501Y, E484K, K417N for Omicron, UK, South African, and Brazilian variants. Download manual or contact info@sacace.com.
-
Sacace Biotechnologies launches SaMag-96 extraction system
It extracts RNA/DNA from 96 samples for COVID-19 testing in 30 minutes using M-Sorb-S kit.
-
Sacace introduces COVID-19 SARS-Cov-2 Real-TM kit
The multiplex Real Time PCR kit detects E-gene, N-gene, SARS-like viruses, and Internal Control in clinical samples. User manual available. Contact info@sacace.com for orders.
-
Sacace releases new Molecular Genetics kits
Real Time PCR kits detect genetic variants for diseases. Platform independent, compatible with Rotor-Gene, CFX, and others. Examples include FV Leiden, FII Protrombin, MTHFR SNPs.
Media coverage
-
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements
Why Adaptive Biotechnologies Stock Is Back in Focus Adaptive Biotechnologies (ADPT) is drawing attention after fourth quarter 2025 results topped analyst expectations, supported by its...
-
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine research firms that are covering the...
-
BioNTech founders plan exit to set up new venture, shares slump | Reuters
BioNTech's two co-founders and leading executives will leave the COVID-19 vaccine maker by the end of the year to start a new venture, driving the...
-
Adaptive Biotechnologies CEO Sells Over $8 Million in Company Stock — TradingView News
Adaptive Biotechnologies Corp CEO and Chairman, Chad M Robins, reported selling 524,998 shares of company stock, totaling approximately $8,320,613. These transactions occurred on February 27...
Track Sacace Biotechnologies and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Sacace Biotechnologies competitors & trending companies
Browse news for competitors to Sacace Biotechnologies and other trending companies.
Sussex Biologicals
Advanced Molecular Diagnostics
DYNEX
Biomol Laboratories
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI